Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Sep;9(3):162-171.
doi: 10.1055/s-0040-1705133. Epub 2020 Mar 6.

Sugammadex: Applications in Pediatric Critical Care

Joseph D Tobias  1   2   3
Affiliations
Review

Sugammadex: Applications in Pediatric Critical Care

Joseph D Tobias. J Pediatr Intensive Care. 2020 Sep.

Abstract

Sugammadex is a novel pharmacologic agent, which reverses neuromuscular blockade with a mechanism that differs from acetylcholinesterase inhibitors such as neostigmine. There is a growing body of literature demonstrating its efficacy in pediatric patients of all ages. Prospective trials have demonstrated a more rapid and more complete reversal of rocuronium-induced neuromuscular blockade than the acetylcholinesterase inhibitor, neostigmine. Unlike the acetylcholinesterase inhibitors, sugammadex effectively reverses intense or complete neuromuscular blockade. It may also be effective in situations where reversal of neuromuscular blockade is problematic including patients with neuromyopathic conditions or when acetylcholinesterase inhibitors are contraindicated. This article reviews the physiology of neuromuscular transmission as well as the published literature, regarding the use of sugammadex in pediatric population including the pediatric intensive care unit population. Clinical applications are reviewed, adverse effects are discussed, and dosing algorithms are presented.

Keywords: neostigmine; neuromuscular blockade; sugammadex; train-of-four monitoring.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest None declared.

References

    1. Sharpe M D. The use of muscle relaxants in the intensive care unit. Can J Anaesth. 1992;39(09):949–962. - PubMed
    1. Adelson P D, Bratton S L, Carney N Aet al.Guidelines for the acute medical management of severe traumatic brain injury in infants, children, and adolescents. Chapter 9. Use of sedation and neuromuscular blockade in the treatment of severe pediatric traumatic brain injury Pediatr Crit Care Med 20034(3, Suppl):S34–S37. - PubMed
    1. Rhoney D H, Murry K R. National survey on the use of sedatives and neuromuscular blocking agents in the pediatric intensive care unit. Pediatr Crit Care Med. 2002;3(02):129–133. - PubMed
    1. Greenberg S B, Vender J. The use of neuromuscular blocking agents in the ICU: where are we now? Crit Care Med. 2013;41(05):1332–1344. - PubMed
    1. Chamorro C, Borrallo J M, Romera M A, Silva J A, Balandín B. Anesthesia and analgesia protocol during therapeutic hypothermia after cardiac arrest: a systematic review. Anesth Analg. 2010;110(05):1328–1335. - PubMed